Quarterly Report I 17/18
September 2017 – November 2017, Diamyd Medical AB (publ), Fiscal year 2017/2018September 1, 2017 – November 30, 2017 · R&D-expenses amounted to MSEK -7.6 (-2.0). The cost increase compared with the previous year relates to the preparation of the DIAGNODE-2 trial and production of GAD-65 · Net result amounted to MSEK -10.8 (-4.3) · Result per share, before and after dilution, amounted to SEK -0.2 (-0.1) · Cash flow from operating activities amounted to MSEK -12.1 (-4.7) · Liquid assets and short-term investments amounted as of November 30 to MSEK 73.7 (26.4) Significant
